Sagimet Biosciences (SGMT)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
-$0.12 (-2.15%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of Sagimet Biosciences (SGMT)
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company focused on developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. The company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH).

Key Insights

Critical company metrics and information

  • Share Price

    $5.09

  • Market Cap

    $164.04 Million

  • Total Outstanding Shares

    30.68 Million Shares

  • Total Employees

    10

  • Dividend

    No dividend

  • IPO Date

    July 14, 2023

  • SIC Description

    Pharmaceutical Preparations

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Phone Number

    (650) 561-8600

  • Address

    155 bovet rd., suite 303, San mateo, CA, 94402

  • Homepage

    https://www.sagimet.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$-18.95 Million
Net Cash Flow From Financing Activities, Continuing$0.00
Net Cash Flow From Investing Activities, Continuing$624,000.00
Net Cash Flow$-18.95 Million
Net Cash Flow From Financing Activities$0.00
Net Cash Flow From Investing Activities$624,000.00

Income Statement

July 1, 2024 to September 30, 2024
MetricValue
Net Income/Loss Available To Common Stockholders, Basic$-14.62 Million
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations Before Tax$-14.62 Million
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Earnings Per Share$-0.45
Income/Loss From Continuing Operations After Tax$-14.62 Million

Balance Sheet

July 1, 2024 to September 30, 2024
MetricValue
Wages$995,000.00
Equity Attributable To Noncontrolling Interest$0.00
Liabilities And Equity$174.78 Million
Other Current Liabilities$1.95 Million
Current Liabilities$4.09 Million
Assets$174.78 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2025 Financhle. All Rights Reserved.